

SAFETY DATA SHEET



1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	FLIXONASE NASAL DROPS
Synonym(s)	FLIXONASE NASAL DROPS 400 MCG * FLIXONASE NASULES * FLUTIDE NASETEN 0.4 MG NASENTROPFEN * FLUTICASONE PROPIONATE, FORMULATED PRODUCT
Company Name	<p>GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK</p> <p>UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response</p> <p>GlaxoSmithKline, Corporate Environment, Health & Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US</p> <p>US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response</p>

* 2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
FLUTICASONE PROPIONATE	80474-14-2	0.1	
NON-HAZARDOUS INGREDIENTS	Unassigned	99.9	

3. HAZARDS IDENTIFICATION

Fire and Explosion	This product is classified as non-flammable.
Health	Caution - Potent pharmaceutical agent. Health effects information is based on hazards of components. May cause steroid withdrawal rash.
Environment	No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.

Material FLIXONASE NASAL DROPS

Eye Contact Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre. Medical treatment in cases of overexposure should be treated as an overdose of glucocorticosteroid.

Medical Conditions Caused or Aggravated by Exposure Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product.

Antidotes No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards Not expected for the product, although the packaging is combustible.

Extinguishing Media No special requirements needed.

Special Firefighting Procedures For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.

Hazardous Combustion Products Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods Collect and place it in a suitable, properly labelled container for recovery or disposal.

Decontamination Procedures No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

General Requirements No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

INGREDIENT FLUTICASONE PROPIONATE

GSK Occupational Hazard Category 4

GSK Occupational Exposure Limit 3 mcg/m³ (8 HR TWA) SKIN

ENGINEERING CONTROLS

Exposure Controls An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Refer to the Exposure Control Matrix for more information about how ECA's are assigned and how to interpret them.

Containment Consider use of enclosures.

PERSONAL PROTECTIVE EQUIPMENT

Eye Protection Wear approved safety glasses with side shields if eye contact is possible.

Material FLIXONASE NASAL DROPS

Other Equipment or Procedures Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical Form Solution.

10. STABILITY AND REACTIVITY

Stability This product is expected to be stable.

Conditions to Avoid None for normal handling of this product.

11. TOXICOLOGY INFORMATION

Pharmacological Effects This material is a selective glucocorticoid receptor agonist. Adverse effects of overexposure might include: suppression of adrenal glands; temporary decrease in white blood cell counts; symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing); increased susceptibility to infection.

Target Organ Effects Adverse effects might occur in the following organ(s) following overexposure: adrenal glands; immune system.

Routes of Exposure

Oral Toxicity Not expected to be toxic following ingestion.

Skin Effects Irritation is not expected following direct contact. Pharmacological effects may occur following skin absorption.

Eye Effects Minor irritation might occur following direct contact with eyes.

Sensitisation Allergic skin reactions might occur following dermal exposure. Assessment based upon information from human exposure.

Genetic Toxicity Not expected to be genotoxic under occupational exposure conditions.

Carcinogenicity Not expected to produce cancer in humans under occupational exposure conditions. No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.

Reproductive Effects Not expected to produce adverse effects on fertility or development under occupational exposure conditions.

Other Adverse Effects None known for occupational exposure.

12. ECOLOGICAL INFORMATION

Summary This material contains an active pharmaceutical ingredient that has had limited testing and no adverse environmental effects were observed in the tests conducted. There is insufficient information to determine the scope of the environmental effects this material may cause. Until there is additional testing to determine other potential adverse effects on the environment, appropriate precautions should be taken to limit release of this compound to the environment. Local regulations and procedures should be consulted prior to environmental release.

Specific information on the active pharmaceutical ingredient is provided below.

ECOTOXICITY

Aquatic

Activated Sludge Respiration This material contains an active pharmaceutical ingredient that is not toxic to activated sludge microorganisms.

IC50: > 1000 mg/l, 3 Hours, Activated sludge

Daphnid No toxicity to daphnids was observed for the active pharmaceutical ingredient in this mixture, but the upper range of the test was limited by the low water solubility of this compound.

EC50: > 0.55 mg/l, 48 Hours, Daphnia magna, Static test

Material FLIXONASE NASAL DROPS**Terrestrial****Earthworm**

This mixture contains an active pharmaceutical ingredient that is not toxic to earthworms.

EC50: > 1000 mg/kg, 28 Days, Eisenia foetida, manure worm,

MOBILITY**Solubility**

This material contains an active pharmaceutical ingredient that for environmental fate predictions has very low solubility in water.

Volatility

This material contains an active pharmaceutical ingredient that will not readily enter into the air from hard surfaces or from a container of the pure substance.

Adsorption

This material contains an active pharmaceutical ingredient that is likely to adsorb to soil or sediment. This material contains an active pharmaceutical ingredient that is likely to adsorb to sludges and other biomass.

Soil Sediment Sorption (log Koc): 3.41 to 3.83, Measured

Sludge Biomass Distribution Coefficient (log Kd): 3.13 to 3.55 Estimated

Partitioning

This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient will not have the tendency to distribute into fats.

PERSISTENCE/DEGRADATION**Hydrolysis**

This material contains an active pharmaceutical ingredient that has been shown to be chemically stable in water. Hydrolysis is unlikely to be a significant depletion mechanism.

Half-Life, Neutral: > 1 Years, Measured

Biodegradation

This material contains an active pharmaceutical ingredient that is not readily biodegradable but is inherently biodegradable (as defined by 1993 OECD Testing Guidelines) and is not expected to persist in the environment.

Aerobic - Ready

Percent Degradation: < 44 %, 28 days

Aerobic - Soil

Percent Degradation: 9 to 50 %, 64 days

Bioaccumulation

This material contains an active pharmaceutical ingredient that will not have a tendency to bioaccumulate in the food chain.

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations

Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements

Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling**Transport Information**

Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification This product is classified as hazardous according to the OSHA Hazard Communication Standard.

Other US Regulations

TSCA Status Exempt

16. OTHER INFORMATION

References GSK Hazard Determination

SDS Version Number 8

SDS Sections Updated**Sections**

COMPOSITION / INFORMATION ON INGREDIENTS

Subsections

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.